

1FW
Certificate of Mailing (37 C.F.R. §1.8);
I hereby certify that this correspondence is being
deposited with the United States Postal Service as
First Class Mail in an envelope addressed to:
Commissioner for Patents, PO Box 1450, Alexandria,
VA 22313-1450, on this 7th day of February 2005.

s/

Julie Agozino

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
STEVEN LEE BENDER, et al.

Group Art Unit: 1646

Serial No.: 10/824,982

Examiner: Not Yet Assigned

Confirmation No.: 8346

Filed: April 15, 2004

**For: CRYSTAL STRUCTURE OF
VEGFRKD: LIGAND COMPLEXES AND
METHODS OF USE THEREOF**

Mail Stop: Amendment
Honorable Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. § 1.97(b) or 1.97(c)

37 CFR § 1.97(b)

- ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

37 CFR § 1.97(c)

- ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of (1) a Final Action under § 1.113; (2) a Notice of Allowance under § 1.311; or (3) an action that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the fee as set forth in § 1.17(p) to Deposit Account Number 500329.

- ☐ Applicant requests that the Examiner consider the following copending applications:


Application Serial No.	Filing Date

- ☐ Copies of these copending applications are enclosed.
- ☒ Applicant hereby requests consideration of the Information Disclosure Statement, USPTO form 1449, submitted herewith. Copies of the cited references, except as noted below, are enclosed.
- ☐ This application is a continuation, divisional or continuation-in-part of Serial No. [REDACTED]. Copies of the cited references, if not enclosed, are available in the file of the parent application or parents thereof.
- ☐ Copies of U.S. Patents and U.S. Patent Application Publications are not enclosed. (waiver of 37 CFR 1.98(a)(2)(iii) pursuant to 37 CFR 1.183).
- ☒ Applicant hereby requests consideration of the enclosed International Search Report, which was received in a related international patent application.

The Commissioner is hereby authorized to charge any fee deficiency, including any fee required under 37 C.F.R. § 1.17(p), or credit any overpayment, to Deposit Account Number 500329. A duplicate copy of this form is enclosed.

Respectfully submitted,

Date: 2/2/05


Matthew J. Pugmire
Attorney For Applicant
Registration No. 54,723

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 638-6349
Fax: (858) 678-8233

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1209/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application Number	10/824,982
Filing Date	April 15, 2004
First Named Inventor	Steven Lee Bender
Art Unit	1646
Examiner Name	TBA
Attorney Docket Number	PC19173A

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ²			
	AA	6,316,603	11-13-2001	Michael A. McTigue, et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	AB	WO 95/21613	08-17-1995	Sugen, Inc.		
	AC	WO 00/14105	03-16-2000	Agouron Pharmaceuticals, Inc.		
	AD	WO 00/75120	12-14-2000	Agouron Pharmaceuticals, Inc.		
	AE	WO 01/02369	01-11-2001	Agouron Pharmaceuticals, Inc.		
	AF	WO 01/02359	01-11-2001	Ajinomoto Co., Inc.		
	AG	WO 01/53274	07-26-2001	Agouron Pharmaceuticals, Inc.		
	AH	WO 01/72778	10-04-2001	Basf Aktiengesellschaft		
	AI	WO 02/20734	03-14-2002	Glaxo Group Ltd.		
	AJ	EP 1 243 596	09-25-2002	Agouron Pharmaceuticals, Inc.		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application Number	10/824,982
Filing Date	April 15, 2004
First Named Inventor	Steven Lee Bender
Art Unit	1646
Examiner Name	TBA
Attorney Docket Number	PC19173A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AK	ABRAHAM, J., et al., "Methods Used In The Structure Determination Of Bovine Mitochondrial F ₁ ATPase", <i>Acta Cryst.</i> , 1996, 30-42, D55.	
	AL	ALTSCHUL, S., et al., "Basic Local Alignment Search Tool," <i>J. Mol. Biol.</i> , 1990, 403-410, vol. 215.	
	AM	ALTSCHUL, S., et al., "Gapped BLAST And PSI-BLAST: A New Generation Of Protein Database Search Programs," <i>Nucleic Acids Research</i> , 1997, 3389-3402, vol. 25, no. 17.	
	AN	AMANN, E., et al., "Tightly Regulated <i>tac</i> Promoter Vectors Useful For the Expression Of Unfused And Fused Proteins In <i>Escherichia coli</i> ," <i>Gene</i> , 1988, 301-315, vol. 69.	
	AO	APPLET, K., "Crystal Structures Of HIV-1 Protease-Inhibitor Complexes," <i>Perspectives In Drug Discovery And Design</i> , 1993, 23-48, vol. 1.	
	AP	BALDARI, C., et al., "A Novel Leader Peptide Which Allows Efficient Secretion Of A Fragment Of Human Interleukin 1 β In <i>Saccharomyces Cerevisiae</i> ," <i>The EMBO Journal</i> , 1987, 229-234, vol. 6.	
	AQ	BARTLETT, P., et al., "CAVEAT: A Program To Facilitate The Structure-Derived Design Of Biologically Active Molecules," <i>Molecular Recognition In Chemical And Biological Problems</i> , Royal Chemical Society, 1989, 182-196, vol. 78.	
	AR	BOHM, H., et al., "The Computer Program LUDI: A New Method For The De Novo Design Of Enzyme Inhibitors," <i>Journal Of Computer-Aided Molecular Design</i> , 1992, 61-78, vol. 6.	
	AS	BOUZIDA, D., et al., "Thermodynamics And Kinetics Of Ligan-Protein Binding Studied With The Weighed Histogram Analysis Method And Simulated Annealing," <i>Pacific Symposium On Biocomputing</i> , '99, 426-437, vol. 99, World Scientific, New Jersey.	
	AT	BOWIE, J., et al., "Deciphering The Message In Protein Sequences: Tolerance To Amino Acid Substitutions," <i>Science</i> , 1990, 1306-1310, vol. 247.	
	AU	BOYER, S., et al., "Small Molecule Inhibitors Of KDR (VEGFR-2) Kinase: An Overview Of Structure Activity Relationships," <i>Current Topics In Medicinal Chemistry</i> , 2002, 973-1000, vol. 2 no. 9.	
	AV	BUGG, E., et al., "Structure-based Design, An Innovative Approach To Developing Drugs, Has Recently Spawned Many Promising Therapeutic Agents, Including Several Now In Human Trials For Treating AIDS, Cancer And Other Diseases," <i>Scientific American</i> , 1993, 92-98.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/824,982
Filing Date	April 15, 2004
First Named Inventor	Steven Lee Bender
Art Unit	1646
Examiner Name	TBA
Attorney Docket Number	PC19173A

AW	COHEN, N., et al., "Molecular Modeling Software And Methods For Medicinal Chemistry," <i>Journal of Medicinal Chemistry</i> , 1990, 883-895, vol. 33, no. 3.
AX	CUNNINGHAM, B., et al., "High-Resolution Epitope Mapping Of hGH-Receptor Interactions By Alanine-Scanning Mutagenesis," <i>Science</i> , 1989, 1081-1085, vol. 244.
AY	DE LA FORTELLE, E., et al., "Maximum-Likelihood Heavy-Atom Parameter Refinement For Multiple Isomorphous Replacement And Multiwavelength Anomalous Deffraction Methods," <i>Methods In Enzmology</i> , 1997, 472-494, vol. 276.
AZ	DEVEREUX, J., et al., "A Comprehensive Set Of Sequence Analysis Programs For The VAX," <i>Nucleic Acids Res.</i> , 1984, 387, vol. 12, no. 1.
BA	DE VOS, A., et al., "Human Growth Hormone And Extracellular Domain Of Its Receptor: Crystal Structure Of The Complex," <i>Science</i> , 1992, 306-312, vol. 255.
BB	DUNBRACK, R., et al., "A Comprehensive Set Of Sequence Analysis Programs For The VAX," "Meeting Review: The Second Meeting On The Critical Assessment Of Techniques For Protein Structure Prediction (CASP2), Asilomar, California, December 13-16, 1996," <i>Folding & Design</i> , 1997, R27-R42, vol. 2, no. 2.
BC	EISEN, M., et al., "HOOK: A Program For Finding Novel Molecular Architectures That Satisfy The Chemical And Steric Requirements Of A Macromolecule Binding Site," <i>Proteins: Structure Function, and Genetics</i> , 1994, 199-221, vol. 19.
BD	ELDRIDGE, M., et al., "Empirical Scoring Functions: I. The Development Of A Fast Empirical Scoring Function To Estimate The Binding Affinity Of Ligands In "Receptor Complexes," <i>Journal Of Computer-Aided Molecular Design</i> , 1997, 425-445, vol. 11.
BE	ERICKSON, J., et al., "Design And Structure Of Symmetry-based Inhibitors Of HIV-1 Protease," <i>Perspectives In Drug Discovery And Design</i> , 1993, 109-128, vol. 1.
BF	EWING, T., et al., "DOCK 4.0: Search Strategies For Automated Molecular Docking Of Flexible Molecule Databases," <i>Journal Of Computer-Aided Molecular Design</i> , 2001, 411-428, vol. 15.
BG	FERRARA, N., et al., "The Biology Of Vasular Endothelial Growth Factor," <i>Endocrine Reviews</i> , 1997, 4-25, vol. 18, no. 1.
BH	FOLKMAN, J., et al., "What Is The Evidence That Tumors Are Angiogenesis Dependent?," <i>Journal Of The National Cancer Institute</i> , 1990, 4-6, vol. 83, no. 1.
BI	GEHLHAAR, D., et al., "Molecular Recognition Of The Inhibitor AG-1343 By HIV-1 Protease: Conformationally Flexible Docking By Evolutionary Programming," <i>Chemistry & Biology</i> , 1995, 317-324, vol. 2, no. 5.
BJ	GEHLHAAR, D., et al., Proceedings Of The Seventh Ann. Conf. On Evolutionary Programming, 1998, The MIT Press, Cambridge, MA.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Complete if Known

Application Number	10/824,982
Filing Date	April 15, 2004
First Named Inventor	Steven Lee Bender
Art Unit	1646
Examiner Name	TBA
Attorney Docket Number	PC19173A

BK	GERWINS, P., et al., "Function Of Fibroblast Growth Factors And Vascular Endothelial Growth Factors And Their Receptors In Angiogenesis, <i>Critical Reviews In Oncology Hematology</i> , 2000, 185-194, vol. 34.
BL	GILLET, V., et al., "SPROUT: A Program For Structure Generation," <i>Journal Of Computer-Aided Molecule Design</i> , 1993, 127-153, vol. 7.
BM	GOODFORD, P., et al., "A Computational Procedure For Determining Energetically Favorable Binding Sites On Biologically Important Macromolecules," <i>J. Med. Chem.</i> , 1985, 849-857, vol. 28, no. 7.
BN	GOODSELL, D., et al., "Automated Docking Of Flexible Ligands: Applications Of AutoDock," <i>Journal Of Molecular Recognition</i> , 1996, 1-5, vol. 9.
BO	GOODSELL, D., et al., "Automated Docking Of Substrates To Proteins By Simulated Annealing," <i>Proteins: Structure, Function And Genetics</i> , 1990, 195-220, vol. 8.
BP	GOTTESMAN, S., et al., "minimizing Proteolysis In <i>Escherichia Coli</i> : Genetic Solutions," <i>Methods In Enzymology</i> , 1990, 119-128, vol. 185.
BQ	GUIDA, W., et al., "Software For Structure-Based Drug Design," <i>Current Opinion In Structural Biology</i> , 1994, 777-781, vol. 4.
BR	HORI, A., et al., "Suppression Of Solid Tumor Growth By Immunoneutralizing Monoclonal Antibody Against Human Basic Fibroblast Growth Factor," <i>Cancer Research</i> , 1991, 6180-6184, vol. 51, no. 22.
BS	HUBBARD, S., et al., "Crystal Structure Of The Tyrosine Kinase Domain Of The Human Insulin Receptor," <i>Nature</i> , 1994, 746-754, vol. 372, no. 22.
BT	JOHNSON, L., et al., "Active And Inactive Protein Kinases: Structural Basis For Regulation, <i>Cell</i> , 1996, 149-158, vol. 85.
BU	JONES, T., et al., "Improved Methods For Building Protein Models In Electron Density Maps And The Location Of Errors In These Models," <i>ACTA Cryst.</i> , 1991, 110-119, A47.
BV	JONES, G., et al., "Development And Validation Of A Genetic Algorithm For Flexible Docking," <i>J. Mol. Biol.</i> , 1997, 727-748, vol. 267.
BW	JONES, G., et al., "Molecular Recognition Of Receptor Sites Using A Genetic Algorithm With A Description Of Desolvation," <i>J. Mol. Biol.</i> , 1995, 43-53, vol. 245.
BX	KAN, C., et al., "Heterologous Expression And Purification Of Active Human Phosphoribosylglycinamide Formyltransferase As A Single Domain," <i>Journal Of Protein Chemistry</i> , 1992, 467-473, vol. 11, no. 5.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/824,982
Filing Date	April 15, 2004
First Named Inventor	Steven Lee Bender
Art Unit	1646
Examiner Name	TBA
Attorney Docket Number	PC19173A

BY	KAUFMAN, R., et al., "Translational Efficiency Of Polycistronic mRNAs And Their Utilization To Express Heterologous Genes In Mammalian Cells," <i>The EMBO Journal</i> , 1987, 187-195, vol. 6, no. 1.
BZ	KIM, K., et al., "Inhibition Of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth <i>In Vivo</i> ," <i>Nature</i> , 1993, 841-844, vol. 362.
CA	KIM, J., et al., "X-ray Crystallographic Studies Of The VEGFR-2 Kinase Domain In Complex With Small Molecule Inhibitors," <i>Proceedings Of The American Association For Cancer Research Annual Meeting</i> , 2000, 483.
CB	KISSINGER, C., et al., "Rapid Automated Molecular Replacement By Evolutionary Search," <i>Acta Crystallographica Section D Biological Crystallography</i> , 1999, 484-491, D55.
CC	KNIGHTON, D., et al., "Crystal Structure Of The Catalytic Subunit Of Cyclic Adenosine Monophosphate-Dependent Protein Kinase," <i>Science</i> , 1991, 407-413, vol. 253.
CD	KUNKEL, T., et al., "Rapid And Efficient Site-Specific Mutagenesis Without Phenotypic Selection," <i>Proc. Natl. Acad. Sci. USA</i> , 1985, 488-492, vol. 82.
CE	KUNTZ, I., et al., "A Geometric Approach To macromolecule-Ligan Interactions," <i>J. Mol. Biol.</i> , 1982, 269-288, vol. 161.
CF	KURJAN, J., et al., "Structure Of A Yeast Pheromone Gene (MF α): A Putative α -Factor Precursor Contains Four Tandem Copies Of Mature α -Factor." <i>Cell</i> , 1982, 933-943, vol. 30.
CG	LAIRD, A., et al., "SU6668 Is A Potent Antiangiogenic And Antitumor Agent That Induces Regression Of Established Tumors," <i>Cancer Research</i> , 2000, 4152-4160, vol. 60.
CH	LAM, P., et al., "Rational Design Of Potent, Bioavailable, Nonpeptide Cyclic Ureas As HIV Protease Inhibitors," <i>Science</i> , 1994, 380-384, vol. 263.
CI	LAMZIN, V., et al., "Automated Refinement Of Protein Models," <i>Acta Cryst.</i> , 1993, 129-147, D49.
CJ	LATTMAN, E., et al., "Use Of The Rotation And Translation Functions," <i>Methods In Enzymology</i> , 1985, 55-77, vol. 115.
CK	LAURI, G., et al., CAVEAT: a Program To Facilitate The Design Of Organic Molecules*, <i>Journal of Computer- Aided Mol. Design</i> , 1994, 51-66, vol. 8.
CL	LUCKLOW, V., et al., "High Level Expression Of Nonfused Foreign Genes With <i>Autographa Californica</i> Nuclear Polyhedrosis Virus Expression Vectors," <i>Virology</i> , 1989, 31-39, vol. 170.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/824,982
Filing Date	April 15, 2004
First Named Inventor	Steven Lee Bender
Art Unit	1646
Examiner Name	TBA
Attorney Docket Number	PC19173A

CM	MANLEY, P., et al., "Advances In The Structural Biology, Design And Clinical Development Of VEGF-R Kinase Inhibitors For The Treatment Of Angiogenesis," <i>Biochemica Et Biophysica ACTA</i> , 2004, 17-27, vol. 1697.
CN	MARTIN, Y., et al., "3D Database Searching In Drug Design," <i>Journal of Medicinal Chemistry</i> , 1992, 2145-2154, vol. 35, no. 12.
CO	MC TIGUE, M., et al., "Crystal Structure Of The Kinase domain Of Human Vascular Endothelial Growth Factor Receptor 2: A Key Enzyme In Angiogenesis," <i>Structure</i> , 1999, 319-330, vol. 7, no. 3.
CP	MENG, E., et al., "Automated Docking With Grid-Based Energy Evaluation," <i>Journal of Computational Chemistry</i> , 1992, 505-524, vol. 13, no. 4.
CQ	MEYERS, E., et al., "Optimal Alilgnments In Linear Space," <i>CABIOS</i> , 1988, 11-17, vol. 4, no. 1.
CR	MILLAUER, B., et al., Glioblastoma Growth Inhibited <i>In Vivo</i> By A Dominant-negative Flk-1 Mutant," <i>Nature</i> , 1994, 576-579, vol. 367.
CS	MIRANKER, A., et al., "Functionality Maps Of Binding Sites: A Multiple Copy Simultaneous Search Method," <i>PROTEINS: Structure, Function And Genetics</i> , 1991, 29-34, vol. 11.
CT	MOHAMMADI, M., et al., "Structures Of The Tyrosine Kinase Domain Of Fibroblast Growth Factor Receptor In Complex With Inhibitors," <i>Science</i> , 1997, 955-960, vol. 276, no. 5314.
CU	MULLIS, K., et al., "Specific Enzymatic Amplification Of DNA In Vitro: The Polymerase Chain Reaction," <i>Biotechnology</i> , 1992, 17-27, vol. 24.
CV	NAVAZA, J., et al., "AMoRe: An Automated Package For Molecular Replacement," <i>Acta Cryst. A50</i> , 1994, 157-163.
CW	NAVIA, M., et al., "Use Of Structural Information In Drug Design," <i>Current Opinion In Structural Biology</i> , 1992, 202-210, vol. 2.
CX	NEEDLEMAN, S., et al., "A General Method Applicable To The Search For Similarities In The Amino Acid Sequence Of Two Proteins," <i>J. Mol. Biol.</i> , 1970, 443-453, vol. 48.
CY	OTWINOWSKI, Z., et al., "Processing Of X-Ray Diffraction Data Collected In Oscillation Mode," <i>Methods In Enzymology</i> , 1997, 307-326, vol. 276.
CZ	PARAST, C., et al., "Characterization And Kinetic Mechanism Of Catalytic Domain Of Human Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase (VEGFR2 TK), A Key Enzyme In Angiogenesis," <i>Biochemistry</i> , 1998, 16788-16801, vol. 37, no. 47.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application Number	10/824,982
Filing Date	April 15, 2004
First Named Inventor	Steven Lee Bender
Art Unit	1646
Examiner Name	TBA
Attorney Docket Number	PC19173A

DA	PARGELLIS, C., et al., "Inhibition Of p38 MAP Kinase By Utilizing A Novel Allosteric Binding Site," <i>Nature Structural Biology</i> , 2002, 268-272, vol. 9, no. 4.
DB	PERRAKIS, A., et al., "Automated Protein Model Building Combined With Iterative Structure Refinement," <i>Nature Structural Biology</i> , 1999, 458-463, vol. 6, no. 5.
DC	PFLUGRATH, J., "The Finer Things In X-ray Diffraction Data Collection," <i>Acta Crystallographica Section D Biological Crystallography</i> , 1999, 1718-1725, D55.
DD	RATTAN, S., et al., "Protein Synthesis, Posttranslational Modifications And Aging," <i>Annals New York Academy Of Sciences</i> , 1992, 48-62, vol. 663.
DE	RITCHIE, D., et al., "Protein Docking Using Spherical Polar Fourier Correlations," <i>Proteins: Structure Function & Genetics</i> , 2000, 178-194, vol. 39.
DF	SCHINDLER, T., et al., "Structural Mechanism For STI-571 Inhibition Of Abelson Tyrosine Kinase," <i>Science</i> , 2000, 1938-1942, vol. 289.
DG	SCHONER, B., et al., "Translation Of A Synthetic Two-cistron mRNA In <i>Escherichia Coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 1986, 8506-8510, vol. 83.
DH	SCHULTZ, L., et al., "Expression And Secretion In Yeast Of A 400-kDa Envelope Glycoprotein Derived From Epstein-Barr Virus," <i>Gene</i> , 1987, 113-123, vol. 54.
DI	SEIFTER, S., et al., "Analysis For Protein Modifications And Nonprotein Cofactors," <i>Methods In Enzymology</i> , 1990, 626-646, vol. 182.
DJ	SHIBUYA, M., et al., "Structure And function Of VEGF/VEGF-Receptor System Involved In Angiogenesis," <i>Cell Structure And Function</i> , 2001, 25-35, vol. 26, no. 1.
DK	SIM, B., et al., "A Recombinant Human Angiostatin Protein Inhibits Experimental Primary And Metastatic Cancer," <i>Cancer Research</i> , 1997, 1329-1334, vol. 57.
DL	SMITH, G., et al., "Production Of Human Beta Interferon In Insect Cells Infected With A Baculovirus Expression Vector," <i>Molecular and Cellular Biology</i> , 1983, 2156-2165, vol.3, no. 12.
DM	SMITH, L., et al., "The Solution Structure Of A Four-Helix Bundle Protein," <i>J. Mol. Biol.</i> , 1992, 899-904, vol. 244.
DN	STUDIER, F., et al., "Use Of T7 RNA Polymerase To Direct Expression Of Cloned Genes," <i>Gene Expression Technology: Methods In Enzymology</i> , 1990, 60-89, vol. 185.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/824,982
Filing Date	April 15, 2004
First Named Inventor	Steven Lee Bender
Art Unit	1646
Examiner Name	TBA
Attorney Docket Number	PC19173A

DO	SUN, L., et al., "Identification Of Substituted 3-(4,5,6,7-Tetrahydro-1H-Indol-2-yl) Methylene)-1, 3-Dihydroindol-2-Ones As Growth Factor Receptor Inhibitors For VEGF-R2 (F1k-1/KDR), FGF-R1 and PDGF-Rbeta Tyrosine Kinases," <i>Journal Of Medicinal Chemistry</i> , 2000, 2655-2663, vol. 43.	
DP	TERMAN, B., et al., "Identification Of The KDR Tyrosine Kinase As A Receptor For Vascular Endothelial Cell Growth Factor," <i>Biochemical and Biophysical Research Communucations</i> , 1992, 1579-1586, vol. 187, no. 3.	
DQ	TRAXLER, P., et al., "Tyrosine Kinases As Targets In Cancer Therapy – Successes And Failures," <i>Expert Opinion On Therapeutic Targets</i> , 2003, 215-234, vol. 7, no. 2.	
DR	WADA, K., et al., "Codon Usage Tabulated From The GenBank Genetic Sequence Data," <i>Nucleic Acids Research</i> , 1992, 2111-2118, vol. 20.	
DS	WEI, L., et al., "Expression, Characterization, and Crystallization Of The Catalytic Core Of The Human Insulin Receptor Protein-tyrosine Kinase Domain," <i>The Journal of Biological Chemistry</i> , 1995, 8122-8130, vol. 270, no. 14.	
DT	WEST, M., "Targeting HIV-1 Protease: A Test Of Drug-design Methodologies," et al., <i>TIPS</i> , 1995, 67-74, vol. 16.	
DU	WHATCHECK, "The CCP4 Suite: Programs For Protein Crystallography," <i>Acta Cryst.</i> , 1994, 760-763, D50.	
DV	WLODAWER, A., et al., "Structure-Based Inhibitors Of HIV-1 Protease ¹ ," <i>Ann. Rev. Biochem.</i> , 1993, 543-585, vol. 62.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.